AI Healthcare Stocks With Real World Medical Use Cases

Transformative AI healthcare stocks sit at the crossroads of two powerful forces investors are watching closely right now: stubborn global inflation risks and rapid adoption of cost saving technology. With central banks adjusting policy paths, energy prices adding pressure, and growth signals mixed across regions, many investors are looking for themes that are less tied to any one country or rate decision. This Transformative AI Healthcare Stocks screener focuses on companies using AI to improve diagnostics, treatment decisions, and efficiency in care delivery. This article highlights 3 notable stocks from that list for investors to consider for further research.

Telescope Innovations (CNSX:TELI)

Overview: Telescope Innovations is a Vancouver based chemical technology company that builds hardware, software, and processes to help pharmaceutical, chemical, and critical minerals clients run, monitor, and analyse complex reactions, including DIRECTINJECT-LC for direct in line sampling. The company also earns revenue from intellectual property and contract research, supported by collaborations with partners such as Pfizer, Standard Lithium, and AGI Group.

Operations: Telescope Innovations generates about CA$7.3 million in revenue from chemicals, with most sales from the United States and smaller contributions from Canada and Europe.

Market Cap: CA$33.9 million

Telescope Innovations may appeal to investors who want exposure to AI enabled lab automation and advanced chemistry tools and who are comfortable with early stage risk. Recent agreements to supply Self Driving Lab platforms to large pharmaceutical clients indicate commercial traction; however, the company is still reporting revenue alongside continuing losses and a return on equity that remains deeply negative. The current price to sales level sits well above peers and the company relies on external borrowing with less than a year of cash runway, so funding risk is front and centre. For investors who can tolerate volatility and dilution, the combination of experienced management, specialist technology and new collaborations may justify a closer look at what the market might be missing.

Telescope Innovations is building traction with Self Driving Lab platforms while still carrying early stage losses and funding questions. It is therefore useful to see how those threads come together in the Telescope Innovations financial health report

Profound Medical (TSX:PRN)

Overview: Profound Medical is a medical device company that uses AI powered, MRI guided systems to precisely heat and destroy diseased tissue without surgical incisions, initially focused on prostate conditions. Its TULSA PRO and Sonalleve platforms are used to ablate or manage tumours and other targeted tissues across multiple indications in hospitals across North America, Europe, and Asia.

Operations: Profound Medical generates about $18.8 million in revenue from Medical Technology, primarily from the United States at $12.3 million, with Canada contributing $5.8 million and Germany $0.7 million.

Market Cap: CA$348.8 million

Profound Medical catches attention in the AI healthcare space because it combines incision free, MRI guided procedures with software that aims to make treatment more accurate and repeatable. The company is still loss making and has funded its growth through external borrowing and fresh equity, which raises questions when paired with a rich P/S multiple and management pay that is high relative to peers. At the same time, growing interest in the TULSA procedure, new board appointments and potential collaboration with Telix Pharmaceuticals point to a business trying to convert specialist technology into a more widely adopted platform that some investors may feel the market is not fully pricing in yet.

Profound Medical’s AI driven, incision free procedures are starting to look like more than just a niche idea. The real question is how that story stacks up against the analyst forecasts for Profound Medical

Perimeter Medical Imaging AI (TSXV:PINK)

Overview: Perimeter Medical Imaging AI develops imaging systems such as the Perimeter S Series and Claire OCT with ImgAssist AI to give surgeons real time, cross sectional views of excised tissue margins in the operating room, particularly for breast conserving surgery. The company also supports hospitals and cancer centers with a proprietary image library and consumable containers that fit into its workflow.

Operations: Perimeter Medical Imaging AI generates about $2.1 million in revenue from Medical Imaging Systems, all from customers in Canada.

Market Cap: CA$47.6 million

Perimeter Medical Imaging AI sits squarely in the Transformative AI Healthcare theme, with AI supported imaging designed to help surgeons judge cancer margins more accurately while the patient is still in theatre. Revenue is still small and the company is loss making with a very high decline in return on equity, funded by higher risk borrowings and recent dilution. This places the company firmly in high risk territory. FDA Premarket Approval for Claire OCT+AI, backed by a large breast tissue image library, external funding for next generation AI work and analyst targets above the current share price indicate that some investors view the current valuation and modest sales base as leaving room for the story to develop further.

Perimeter Medical Imaging AI is attempting to transform a small revenue base and a high-risk balance sheet into a broader narrative focused on AI-supported cancer surgery outcomes, but the real tension sits inside the 2 key rewards and 3 important warning signs (1 is major!)

The three stocks covered here are only a starting point, as the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaced 4 more companies with equally compelling AI in healthcare narratives that could round out your research list. To unlock a wider view of this theme, consider using Simply Wall St to filter for the specific catalysts and narratives discussed here. This can help you identify and analyze the AI healthcare opportunities that best match your approach.

Take Control of Your Investment Journey

If Telescope Innovations or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About What Else You Could Be Exploring?

Fresh opportunities do not stay under the radar for long, and once momentum builds, the best entry points can disappear quickly. Scan these breakout themes before the crowd and consider your next move.

• Spot resilient potential by reviewing companies in the 11 resilient stocks with low risk scores that aim to keep balance sheets steady while others are still getting caught by sudden shocks.
• Explore upside scenarios with the curated 10 high quality undiscovered gems that focuses on businesses still flying beneath most radars while it matters for early entries.
• Track income-focused ideas through the hand picked 6 dividend fortresses so regular cash payouts stay front and center as prices and yields keep shifting.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com